Phathom Pharmaceuticals Debt 2025

Phathom Pharmaceuticals Aktienanalyse

What does Phathom Pharmaceuticals do?

Phathom Pharmaceuticals Inc. is a pharmaceutical company specializing in the development and marketing of medications for the treatment of gastrointestinal disorders. The company is headquartered in Florham Park, New Jersey and was founded in 2016. The company's business model is focused on utilizing its innovative technology and expertise in the medical treatment of gastrointestinal disorders to improve the lives of patients. It works closely with doctors and hospitals to ensure that its products are developed to the highest standards. The company is divided into different business segments to enable optimal patient care and market penetration. The key business segments are: 1. Gastroesophageal reflux disease Phathom has developed a medication called Vonoprazan for the treatment of gastroesophageal reflux disease. This common condition occurs when stomach acid flows back into the esophagus, causing pain, inflammation, and heartburn. The medication blocks the production of stomach acid, thus helping to relieve the symptoms of reflux disease. 2. Helicobacter pylori infection The company has also developed a medication called Ryzodeg for the treatment of Helicobacter pylori infection. This infection, caused by a type of bacteria, can lead to stomach ulcers and other gastrointestinal disorders. Ryzodeg is a combination of an antimicrobial substance and a proton pump inhibitor, which together are more effective than individual medications. 3. Eosinophilic esophagitis Phathom is currently developing a medication for the treatment of eosinophilic esophagitis (EoE), an allergic inflammation of the esophagus that can cause difficulty swallowing, pain, and diarrhea. The medication is currently in the clinical development phase and could soon be on the market. Phathom Pharmaceuticals was founded by a group of experienced executives from the pharmaceutical and biotech industry, including CEO Dr. Azmi Nabulsi and COO Dr. Tuan Ha-Ngoc. Both have extensive experience in the development and marketing of medications and contribute their expertise to the company's management. The company also specializes in partnerships with other pharmaceutical companies and clinical research institutions to advance its research and development. For example, the company has entered into a strategic partnership with Takeda Pharmaceuticals to advance the development and marketing of Vonoprazan. Phathom Pharmaceuticals is a promising company specializing in the development and marketing of medications for the treatment of gastrointestinal disorders. With its innovative technology and experienced management, the company is expected to continue growing in the future and help improve the health of patients around the world. Phathom Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Phathom Pharmaceuticals's Debt Structure

Phathom Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Phathom Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Phathom Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Phathom Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Phathom Pharmaceuticals stock

What is the debt of Phathom Pharmaceuticals this year?

Phathom Pharmaceuticals has a debt level of 63.38 USD this year.

What was the debt of Phathom Pharmaceuticals compared to the previous year?

The debt of Phathom Pharmaceuticals has increased by 28.29% compared to the previous year increased.

What are the consequences of high debt for investors in Phathom Pharmaceuticals?

High debt can pose a risk for investors of Phathom Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Phathom Pharmaceuticals?

Low debt means that Phathom Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Phathom Pharmaceuticals affect the company?

An increase in debt of Phathom Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Phathom Pharmaceuticals affect the company?

A reduction in debt of Phathom Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Phathom Pharmaceuticals?

Some factors that can influence the debt of Phathom Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Phathom Pharmaceuticals so important for investors?

The debts of Phathom Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Phathom Pharmaceuticals take to change the debt?

To change the debt, Phathom Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Phathom Pharmaceuticals pay?

Over the past 12 months, Phathom Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Phathom Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Phathom Pharmaceuticals?

The current dividend yield of Phathom Pharmaceuticals is .

When does Phathom Pharmaceuticals pay dividends?

Phathom Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Phathom Pharmaceuticals?

Phathom Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Phathom Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Phathom Pharmaceuticals located?

Phathom Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Phathom Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Phathom Pharmaceuticals from 1/20/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/20/2025.

When did Phathom Pharmaceuticals pay the last dividend?

The last dividend was paid out on 1/20/2025.

What was the dividend of Phathom Pharmaceuticals in the year 2024?

In the year 2024, Phathom Pharmaceuticals distributed 0 USD as dividends.

In which currency does Phathom Pharmaceuticals pay out the dividend?

The dividends of Phathom Pharmaceuticals are distributed in USD.